Amended Statement of Changes in Beneficial Ownership (4/a)
November 08 2019 - 12:27PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
White Winston Select Asset Fund Series Fund MP-18, LLC |
2. Issuer Name and Ticker or Trading Symbol
MusclePharm Corp
[
MSLP
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director __X__ 10% Owner _____ Officer (give title below) _____ Other (specify below)
|
(Last)
(First)
(Middle)
265 FRANKLIN ST., SUITE 1702, |
3. Date of Earliest Transaction
(MM/DD/YYYY)
9/27/2019
|
(Street)
BOSTON, MA 02115
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
10/2/2019
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
___ Form filed by One Reporting Person
_
X
_ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security (Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code (Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Common Stock
|
9/30/2019
|
|
P
|
|
626826
|
A
|
$0.00
|
3648355 (1)
|
D
|
|
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 3)
|
2. Conversion or Exercise Price of Derivative Security
|
3. Trans. Date
|
3A. Deemed Execution Date, if any
|
4. Trans. Code (Instr. 8)
|
5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
|
6. Date Exercisable and Expiration Date
|
7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)
|
8. Price of Derivative Security (Instr. 5)
|
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)
|
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)
|
11. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
(A)
|
(D)
|
Date Exercisable
|
Expiration Date
|
Title
|
Amount or Number of Shares
|
Explanation of Responses:
|
(1)
|
This Form 4 amends a Form 4 filed by the reporting person on October 2, 2019, which erroneously reported in Table I, Column 5 that the amount of securities beneficially owned following the reported transaction was 3,658,180, rather than 3,648,355.
|
Reporting Owners
|
Reporting Owner Name / Address
|
Relationships
|
Director
|
10% Owner
|
Officer
|
Other
|
White Winston Select Asset Fund Series Fund MP-18, LLC 265 FRANKLIN ST., SUITE 1702 BOSTON, MA 02115
|
|
X
|
|
|
White Winston Select Asset Funds, LLC 265 FRANKLIN ST., SUITE 1702 BOSTON, MA 02110
|
|
X
|
|
|
Enright Todd M. CO WHITE WINSTON SELECT ASSET FUNDS, LLC 265 FRANKLIN ST., SUITE 1702 BOSTON, MA 02110
|
|
X
|
|
|
BLUNDELL MARK CO WHITE WINSTON SELECT ASSET FUNDS, LLC 265 FRANKLIN ST., SUITE 1702 BOSTON, MA 02110
|
|
X
|
|
|
Feagan Donald CO WHITE WINSTON SELECT ASSET FUNDS, LLC 265 FRANKLIN ST., SUITE 1702 BOSTON, MA 02110
|
|
X
|
|
|
Mahoney Robert P CO WHITE WINSTON SELECT ASSET FUNDS, LLC 265 FRANKLIN ST., SUITE 1702 BOSTON, MA 02110
|
|
X
|
|
|
Signatures
|
White Winston Select Asset Fund MP-18, LLC, By: White Winston Select Asset Funds, LLC, its Manager, By: /s/ Todd M. Enright, Manager
|
|
11/8/2019
|
**Signature of Reporting Person
|
Date
|
White Winston Select Asset Funds, LLC, By: /s/ Todd M. Enright, Manager
|
|
11/8/2019
|
**Signature of Reporting Person
|
Date
|
/s/ Todd M. Enright
|
|
11/8/2019
|
**Signature of Reporting Person
|
Date
|
/s/ Mark Blundell
|
|
11/8/2019
|
**Signature of Reporting Person
|
Date
|
/s/ Donald Feagan
|
|
11/8/2019
|
**Signature of Reporting Person
|
Date
|
/s/ Robert P. Mahoney
|
|
11/8/2019
|
**Signature of Reporting Person
|
Date
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
|
*
|
If the form is filed by more than one reporting person, see Instruction 4(b)(v).
|
**
|
Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
|
Note:
|
File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
|
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
|
Muscle Pharm (CE) (USOTC:MSLP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Muscle Pharm (CE) (USOTC:MSLP)
Historical Stock Chart
From Jul 2023 to Jul 2024
See More Message Board Posts
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.